Equities research analysts expect Radius Health Inc (NASDAQ:RDUS) to report sales of $40.49 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Radius Health’s earnings, with the highest sales estimate coming in at $43.00 million and the lowest estimate coming in at $37.59 million. Radius Health posted sales of $22.63 million in the same quarter last year, which suggests a positive year-over-year growth rate of 78.9%. The business is expected to announce its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Radius Health will report full year sales of $170.30 million for the current year, with estimates ranging from $167.05 million to $174.00 million. For the next financial year, analysts expect that the company will post sales of $236.55 million, with estimates ranging from $205.71 million to $256.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Radius Health.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $0.01. The firm had revenue of $29.84 million during the quarter, compared to the consensus estimate of $35.35 million. Radius Health had a negative return on equity of 233.12% and a negative net margin of 176.84%. The firm’s quarterly revenue was up 105.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.11) earnings per share.
In related news, Director Debasish Roychowdhury sold 4,800 shares of the stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $22.15, for a total transaction of $106,320.00. Following the completion of the sale, the director now directly owns 5,500 shares of the company’s stock, valued at $121,825. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Willard H. Dere sold 1,680 shares of the stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $22.22, for a total value of $37,329.60. Following the sale, the director now directly owns 8,620 shares of the company’s stock, valued at $191,536.40. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. State Board of Administration of Florida Retirement System lifted its holdings in shares of Radius Health by 2.9% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 23,460 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 656 shares during the period. Rhumbline Advisers lifted its holdings in shares of Radius Health by 1.4% during the first quarter. Rhumbline Advisers now owns 62,828 shares of the biopharmaceutical company’s stock worth $1,253,000 after purchasing an additional 889 shares during the period. Bank of Montreal Can lifted its holdings in shares of Radius Health by 231.3% during the fourth quarter. Bank of Montreal Can now owns 1,544 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 1,078 shares during the period. Legal & General Group Plc lifted its holdings in shares of Radius Health by 9.4% during the fourth quarter. Legal & General Group Plc now owns 17,227 shares of the biopharmaceutical company’s stock worth $284,000 after purchasing an additional 1,478 shares during the period. Finally, Artisan Partners Limited Partnership lifted its holdings in shares of Radius Health by 1.1% during the first quarter. Artisan Partners Limited Partnership now owns 705,574 shares of the biopharmaceutical company’s stock worth $14,069,000 after purchasing an additional 7,872 shares during the period.
RDUS traded up $0.63 on Wednesday, reaching $24.40. The company’s stock had a trading volume of 8,940 shares, compared to its average volume of 443,047. The company has a quick ratio of 5.04, a current ratio of 5.16 and a debt-to-equity ratio of 6.75. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -4.97 and a beta of 0.99. Radius Health has a fifty-two week low of $12.81 and a fifty-two week high of $31.92.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Story: How to execute a trade ex-dividend strategy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.